Dailypharm Live Search Close

Dong-A ST signs MOU with Israel¡¯s Eleven Therapeutics

By Son, Hyung-Min | translator Kim, Jung-Ju

24.01.10 11:25:47

°¡³ª´Ù¶ó 0
Signs MOU with Israeli Eleven Therapeutics at the JP Morgan Healthcare Conference on the 9th

Will conduct joint research to develop an RNA drug that targets fibrotic diseases


On the 9th, Dong-A ST announced that it had signed a memorandum of understanding (MOU) with Israel-based Eleven Therapeutics to develop an RNA-based gene therapy at the JP Morgan Healthcare Conference in San Francisco, USA.

The two companies will conduct joint research to discover targeted RNA therapies for fibrotic diseases using Eleven Therapeutics' platform technology, TERA. The TERA platform leverages massively parallel processes to map the chemical space and reveal the structure-activity relationship (SAR) of RNA molecules using artificial intelligence (AI)/ machine learning (ML) and is being used to discover optimal xRNA drugs.

Dong-A ST has selected gene therapy as one of its majo

Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)